Supplemental Table 1. Summary of survival outcomes in the galidesivir IM treatment (efficacy experiment 1).

Compound	Day 0 Loading Dose, BID (mg/kg/day)	Dose (mg/kg/day)	Treatment Regimen	Survivors/ Total[a]	Median Survivals[b]
Galidesivir	1000	250	Loading dose 30 min pre-infection, BID, 6 days	0/10	3.5
Galidesivir	800	200		1/10	4
Galidesivir	600	150		2/10	11
Galidesivir	400	100		5/10*	17.5
Placebo		0.1 ml PBS		0/10	3
Ribavirin		100	30 min pre-infection, BID, 8 days	4/10	13.5

[a]Survival totals compared by the two-tailed Fisher's exact test.
[b]Median survivals expressed as the number of days when 50% of the animals survived.
* $P < 0.05$ compared to placebo-treated hamsters.

Supplemental Table 2. Serum biochemistry parameters on day 2 p.i. with RVFV in hamsters treated with galidesivir (efficacy experiment 1).

	Galidesivir Loading / Dose (BID)					
	1000 / 250 mg/kg/day	800 / 200 mg/kg/day	600 / 150 mg/kg/day	400 / 100 mg/kg/day	Placebo	Normal Controls
Blood chemistry						
TP mg/dL	3.7 ± 1.0**	3.2 ± 0.2***	4.4 ± 0.8*	4.7 ± 0.2*	5.9 ± 0.0	6.7 ± 0.9
ALB g/dL	1.9 ± 0.5**	1.6 ± 0.1***	2.2 ± 0.3**	2.4 ± 0.2*	2.8 ± 0.1	3.8 ± 0.9
BUN mg/dL	15.2 ± 59.6	19.9 ± 3.1	13.7 ± 2.3	18.8 ± 2.0	27.9 ± 13.9	27.8 ± 0.6
CRE mg/dL	0.7 ± 0.8	0.3 ± 0.1	0.2 ± 0.1	0.2 ± 0.0	0.4 ± 0.3	0.3 ± 0.1
Ca mg/dL	10.5 ± 1.0	10.7 ± 0.5	10.7 ± 0.6	11.4 ± 0.3	9.9 ± 2.8	11.5 ± 0.8
PHOS mg/dL	9.9 ± 4.4	7.9 ± 0.2	7.3 ± 1.0	7.5 ± 0.2	10.5 ± 3.8	8.3 ± 0.5
AST U/L	609.3 ± 375.1	569 ± 33.8	203.7 ± 43.1	370.7 ±81.4	599.5 ± 566.4	307.5 ± 242.5
ALP U/L	304 ± 145.4	297.7 ± 24.2	172 ± 23.4	136.7 ± 14.6	600 ± 555.8	169 ± 4.2
ALT U/L	552.3 ± 433.3	931 ± 67.1	185.7 ± 65.8	185 ±56.5	619 ± 538.8	428 ± 418.6
GGT U/L	10 ± 0.0	10 ± 0.0	10 ± 0.0	10 ± 0.0	10 ± 0.0	36.5 ± 37.5
GLU mg/dL	153.3 ± 126.2	77.7 ± 18.7	155.3 ± 64.0	148.3 ± 99.7	87.5 ± 75.7	137 ± 18.4
TBIL mg/dl	0.8 ± 0.8	2.5 ± 1.2	0.3 ± 0.2	0.4 ± 0.1	0.3 ± 0.1	1.7 ± 2.0

A comprehensive 12-parameter metabolic blood chemistry analysis was performed on day 2 post-infection (p.i.) serum samples to evaluate liver and kidney function. Tests within the comprehensive panel include: total protein (TP), albumin (ALB), blood urea nitrogen (BUN), creatinine (CREA), calcium (Ca), phosphate (PHOS), aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), glucose (GLU), and total bilirubin (TBIL). Chemistry tests were performed per the manufacturer's recommendations using the DRI-CHEM 4000 (Heska, Des Moines, IA). Data are reported as the group mean and standard deviation. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ compared to the normal controls.

Supplemental Table 3. Summary of survival outcomes in the galidesivir IP treatment (efficacy experiment 2).

Compound	Day 0 Loading Dose, BID (mg/kg/day)	Dose (mg/kg/day)	Treatment Regimen	Survivors/ Total[a]	Median Survivals[b]
Galidesivir	400	100	BID x 6 days	7/10**	undefined
Galidesivir	240	60	BID x 6 days	4/10	10.5
Galidesivir		120	BID x 7 days	3/10	9
Galidesivir	200	100	QD x 6 days	3/10	11.5
Ribavirin		100	BID x 7 days	3/10	16.5
Placebo		0.1 ml LRS	BID x 7 days	0/10	3

[a]Survival totals compared by the two-tailed Fisher's exact test.
[b]Median survivals expressed as the number of days when 50% of the animals survived.
** $P < 0.01$ compared to placebo-treated hamsters.